{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:42:03Z","timestamp":1790764923698,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1053\/j.ajkd.2018.11.012","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T23:23:46Z","timestamp":1551914626000},"page":"56-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["An Ex\u00a0Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome"],"prefix":"10.1053","volume":"74","author":[{"given":"Miriam","family":"Galbusera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Noris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gastoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Breno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cuccarolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Valoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Donadelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Murer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Portalupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1053\/j.ajkd.2018.11.012_bib1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.012_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2018.11.012_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-014-0161-1","article-title":"Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy","volume":"9","author":"Huemer","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2018.11.012_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.012_bib5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2215\/CJN.08520814","article-title":"Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome","volume":"10","author":"Mele","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2018.11.012_bib6","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.012_bib7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2018.11.012_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A\u00a0retrospective study of pregnancy-associated atypical hemolytic uremic syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2018.11.012_bib9","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2018.11.012_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.ajkd.2018.11.012_bib11","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.012_bib12","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2018.11.012_bib13","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/ndt\/gft220","article-title":"Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature","volume":"28","author":"Manenti","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2018.11.012_bib14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.kint.2017.07.015","article-title":"Complete functional characterization of disease-associated genetic variants in the complement factor H gene","volume":"93","author":"Merinero","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2018.11.012_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1681\/ASN.2013121339","article-title":"A\u00a0novel atypical hemolytic uremic syndrome-associated hybrid CFHR1\/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation","volume":"26","author":"Valoti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"15","key":"10.1053\/j.ajkd.2018.11.012_bib16","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1182\/blood-2014-10-609073","article-title":"Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome","volume":"125","author":"Schramm","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.ajkd.2018.11.012_bib17","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.ajkd.2018.11.012_bib18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00467-015-3278-0","article-title":"Liver transplantation for aHUS: still needed in the eculizumab era?","volume":"31","author":"Coppo","year":"2016","journal-title":"Pediatr Nephrol"},{"issue":"23","key":"10.1053\/j.ajkd.2018.11.012_bib19","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.012_bib20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic\u00a0uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2018.11.012_bib21","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10095","key":"10.1053\/j.ajkd.2018.11.012_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.012_bib23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00277-012-1622-z","article-title":"Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation","volume":"92","author":"Carr","year":"2013","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1053\/j.ajkd.2018.11.012_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2018.11.012_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/nep.12931","article-title":"Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab","volume":"22","author":"Choo","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.012_bib26","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1053\/j.ajkd.2018.11.012_bib27","first-page":"45","article-title":"Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report","volume":"3","author":"Ohanian","year":"2011","journal-title":"Clin Pharmacol"},{"issue":"12","key":"10.1053\/j.ajkd.2018.11.012_bib28","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00467-014-2933-1","article-title":"Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency","volume":"29","author":"Michaux","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2018.11.012_bib29","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00277-013-1972-1","article-title":"Successful discontinuation of eculizumab therapy in a patient with aHUS","volume":"93","author":"Pu","year":"2014","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.012_bib30","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00467-017-3612-9","article-title":"Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS","volume":"32","author":"Hackl","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ajkd.2018.11.012_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"issue":"10","key":"10.1053\/j.ajkd.2018.11.012_bib32","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1371\/journal.pmed.0030431","article-title":"Atypical haemolytic uraemic syndrome associated with a hybrid complement gene","volume":"3","author":"Venables","year":"2006","journal-title":"PLoS Med"},{"issue":"1","key":"10.1053\/j.ajkd.2018.11.012_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","article-title":"Standardisation of the factor H autoantibody assay","volume":"219","author":"Watson","year":"2014","journal-title":"Immunobiology"},{"key":"10.1053\/j.ajkd.2018.11.012_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2017.06.007","article-title":"Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab","volume":"183","author":"Puissant-Lubrano","year":"2017","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1053\/j.ajkd.2018.11.012_bib35","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2005101051","article-title":"Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome","volume":"17","author":"Fremeaux-Bacchi","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2018.11.012_bib36","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.ajkd.2018.11.012_bib37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1681\/ASN.2017050518","article-title":"Factor H competitor generated by gene conversion events associates with atypical hemolytic uremic syndrome","volume":"29","author":"Goicoechea de Jorge","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2018.11.012_bib38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2018.11.012_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","article-title":"Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome","volume":"32","author":"Westra","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2018.11.012_bib40","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1053\/j.ajkd.2018.11.012_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/imr.12479","article-title":"Endothelial cells: source, barrier, and target of defensive mediators","volume":"274","author":"Roumenina","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1053\/j.ajkd.2018.11.012_bib42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jim.2016.05.009","article-title":"Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab","volume":"435","author":"Riedl","year":"2016","journal-title":"J\u00a0Immunol Methods"},{"issue":"4","key":"10.1053\/j.ajkd.2018.11.012_bib43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/cpt.686","article-title":"Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment","volume":"102","author":"Volokhina","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.ajkd.2018.11.012_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","article-title":"Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome","volume":"160","author":"Volokhina","year":"2015","journal-title":"Clin Immunol"},{"issue":"21","key":"10.1053\/j.ajkd.2018.11.012_bib45","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.ajkd.2018.11.012_bib46","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.012_bib47","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2018.11.012_bib48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nep.12937","article-title":"Absence of thrombocytopaenia and\/or microangiopathic haemolytic\u00a0anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation","volume":"22","author":"Krishnan","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.012_bib49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.012_bib50","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1084\/jem.20070301","article-title":"Spontaneous hemolytic uremic syndrome triggered by complement\u00a0factor H lacking surface recognition domains","volume":"204","author":"Pickering","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"11","key":"10.1053\/j.ajkd.2018.11.012_bib51","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jmedgenet-2014-102498","article-title":"Factors determining\u00a0penetrance in familial atypical haemolytic uraemic syndrome","volume":"51","author":"Sansbury","year":"2014","journal-title":"J\u00a0Med Genet"},{"issue":"8","key":"10.1053\/j.ajkd.2018.11.012_bib52","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619300034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619300034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:19:33Z","timestamp":1759461573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638619300034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0272638619300034"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.11.012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735297600.793563911","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Ex\u00a0Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}